An RSV vaccine that Moderna is developing significantly reduced the risk of respiratory diseases in a key study, the company said
An experimental vaccine from Moderna Inc. significantly reduced the risk of aamong older adults in a large clinical trial, the latest promising sign in drugmakers’ efforts to fight the deadly RSV virus.
Based on the results, the Cambridge, Mass., company said Tuesday it would apply in the coming months for U.S. regulatory approval to sell its vaccine against RSV, which stands for respiratory syncytial virus. If regulators approve, it could become available by early 2024, the company said.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna says RSV vaccine is 84% effective at preventing disease in older adultsRSV infections kill between 6,000 and 10,000 older adults every year and result in 60,000 to 120,000 hospitalizations, according to the CDC.
Read more »
Human Aversion To Urban Environments Makes CleanTech More Important Than Most ThinkHigh-density living both reduces energy usage and reduces the impact on wild spaces outside of cities. The per capita carbon footprint of people living in a place like New York City is a lot lower than people in Suburbia or further out in the rest of rural America.
Read more »
Twitter Is a Megaphone for ‘Sudden Death’ Vaccine ConspiraciesMisinformation analysts say Twitter, which stopped policing Covid-19 misinformation back in October 2022, has helped to supercharge the ‘sudden death’ vaccine narrative.
Read more »
New Twitter Files reveal pharmaceutical industry lobbied social media over COVID vaccine contentThe latest edition of the Twitter Files showcased Monday how 'the pharmaceutical industry lobbied social media to shape content' related to the COVID vaccine.
Read more »